Provided by Tiger Trade Technology Pte. Ltd.

Terns Pharmaceuticals, Inc.

52.92
-0.2500-0.47%
Post-market: 52.960.0386+0.07%17:56 EDT
Volume:7.92M
Turnover:419.92M
Market Cap:5.77B
PE:-51.29
High:53.08
Open:53.04
Low:52.91
Close:53.17
52wk High:53.19
52wk Low:1.87
Shares:109.00M
Float Shares:80.32M
Volume Ratio:0.35
T/O Rate:9.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0319
EPS(LYR):-1.1175
ROE:-29.12%
ROA:-19.94%
PB:20.31
PE(LYR):-47.35

Loading ...

Enliven up 20% after Terns Pharmaceuticals agrees to be bought by Merck

TIPRANKS
·
Mar 25

BUZZ-U.S. STOCKS ON THE MOVE-Arm, Destiny Tech100, Terns Pharma

Reuters
·
Mar 25

Terns Pharmaceuticals: IF Deal Terminated Under Some Circumstances, Co to Pay Fee of $235 Mln to Merck - SEC Filing

THOMSON REUTERS
·
Mar 25

Merck to Acquire Terns Pharmaceuticals for $6.7 Billion Equity Value

MT Newswires Live
·
Mar 25

Merck braces for Keytruda patent loss with $6.7 billion Terns bet

Reuters
·
Mar 25

Merck to acquire Terns Pharmaceuticals for $53.00 per share in cash, or $6.7B

TIPRANKS
·
Mar 25

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

GlobeNewswire
·
Mar 25

Merck & Co Inc - Deal Approved by Both Boards; Closing Subject to Majority of Terns Stockholders Tendering Shares

THOMSON REUTERS
·
Mar 25

Deals of the day-Mergers and acquisitions

Reuters
·
Mar 25

Terns Pharmaceuticals Shares up 14.1% Premarket After FT Reports Merck Nears $6 Bln Acquisition of Co

THOMSON REUTERS
·
Mar 25

Merck Nears Acquisition of Terns Pharmaceuticals to Strengthen Blood Cancer Treatment Portfolio

Stock News
·
Mar 25

Merck nears $6 billion all-cash deal to buy Terns Pharma, FT reports

Reuters
·
Mar 25

Talks Between Merck and Terns Were at an Advanced Stage and Deal Could Be Reached in Coming Days - FT

THOMSON REUTERS
·
Mar 25

Merck's All-Cash Deal Is Expected to Value Terns at Roughly $6Bn - FT

THOMSON REUTERS
·
Mar 25

U.S. Earnings Preview: After Market Close March 18

Dow Jones
·
Mar 19

Terns Pharmaceuticals CEO Amy L. Burroughs disposes of USD 681,073 in common shares

Reuters
·
Mar 18

Unusually active option classes on open March 13th

TIPRANKS
·
Mar 13

Terns Pharmaceuticals publishes corporate presentation on TERN-701 oral allosteric BCR-ABL inhibitor for CML with 75% MMR at 24 weeks

Reuters
·
Mar 10

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

GlobeNewswire
·
Feb 26

Reaffirming Buy on Terns Pharmaceuticals: Strong Early TERN-701 Data Drive Upgraded Long-Term Revenue Outlook and Upside Potential

TIPRANKS
·
Feb 19